LUNG CANCER:
2006 update

Rodolfo E. Bordoni, MD
Chairman, Research & Therapeutics,
Leader, Lung Cancer Program,
Georgia Cancer Specialists;
Chairman, Professional Education,
Georgia Cancer Foundation;
Chairman, Department of Medicine,
WellStar Kennestone Hospital.

Cancer Death Rates in the U.S. 1930-2000[1]



1 *Cancer Facts and Figures 2005.* Atlanta: American Cancer Society; 2005:1-12.

Lung Cancer in the U.S. in 2005: Incidence and Mortality[1]

- New cases: **172,570** Rank
  - 93,010 males #2
  - 79,560 females #2
- Annual deaths: **163,510**
  - 90,490 males #1
  - 73,020 females #1
- Risk for developing lung cancer

1:13 males	1:18 females

- 5-year survival rate (all stages): **15%**

1 *Cancer Facts and Figures 2005.* Atlanta: American Cancer Society; 2005:1-12.

Frequent Symptoms of Lung Cancer[2]

- Fatigue
- Cough ± hemoptysis
- Dyspnea
- Decreased appetite
- Weight loss
- Pain

2 *Lung Cancer Principles and Practice.* Philadelphia: Lippincott-Raven; 1996:Chapters 18, 23, 26.

Lung Cancer Histology[2]

- **Non-small cell (NSCLC)**
  - Squamous-cell (↓)
  - Adenocarcinoma (↑)
  - BAC (↑)
  - Large-cell
  - Other (NOS)
- **Small-cell (SCLC)**
  - Decreasing incidence
  - Now <15% of all lung cancers



2 *Lung Cancer Principles and Practice.* Philadelphia: Lippincott-Raven; 1996:Chapters 18, 23, 26.

LUNG CANCER:
risk factors

Tobacco…….85%
Second hand smoking
Radon gas
Asbestos…….3-4%
Inflammation/scarring
Family history
Other carcinogens (ether, polycyclic aromatic hydrocarbons, chromium, nickel, organic arsenics



TNM* Staging of NSCLC[3]

Stage IA	T1	N0	M0	
Stage IB	T2	N0	M0	
Stage IIA	T1	N1	M0	
Stage IIB	T2 T3	N1 N0	M0 M0	

*T = primary tumor; N = nodal involvement; M = distant metastasis

3 *Seminars in Surgical Oncology.* 2000;18:106-115.

TNM* Staging of NSCLC (cont)[3]

Stage IIIA	T1-3 T3	N2 N1	M0 M0	
Stage IIIB	T4 Any T	Any N N3	M0 M0	
Stage IV	Any T	Any N	M1	

*T = primary tumor; N = nodal involvement; M = distant metastasis

3 *Seminars in Surgical Oncology.* 2000;18:106-115.

IASLC staging system project:

1997 Lung Cancer Staging System:

1. T3 N0 M0 belongs to Stage- IIB (instead of-IIIA)
2. Malignant pericardial effusion added to T4
3. Satellite tumors within same lobe added to T4
4. Ipsilateral distant metastasis classified as M1

5-year Survival by clinical stage:

IA	IB	IIA	IIB	IIIA	IIIB	IV
72.1 %	**49.9 %**	**48.7 %**	**40.6 %**	**35.8 %**	28.0 %	20.8 %

Based on these, the new staging system most likely will **merge** current TNM stages and will create new **sub-stages** based on a large worldwide database.

LUNG CANCER: *prognostic factors*

Good prognostic factors:

- Early stage
- Good PS
- No weight loss (<5%)
- Female gender

Poor biologic prognostic factors:

- p53 mutation
- K-*ras* oncogene activation

Neutral prognostic factors:

- Age
- Histology (BAC TTF-1+/-/CK20+/-/CK7+/-)

NM/M **M/NM** **NM/M**

(TTF-1+/CK7+/CK20-)

EGFR:

EGFR MUTATION:

NEJM,2004;350:2129 *Lynch T et al.*

- Of 275 pts treated with gefitinib; **25** reached **PR.**
- 9:25 PR pts. *(all AdenoCa & BAC),* with a **MS > 18m**., were evaluated for EGFR gene mutations in the entire gene coding region.

	Responders		Non-Responders
	Cancer Tissue	Normal Tissue	
Mutation	8:9 (88.9%)	**P<0.001**	0:7

Best response: women, non-smokers, BAC histology: 50%!!



Lynch T et al. ; NEJM,2004;350:2129

Mutations were, heterozygous, somatic, either small, in frame deletions or amino acid substitution clustered around the ATP-binding pocket of the TK domain, and located in exons 19 and 21.

EGFR MUTATION-I *(cont'd):*

NEJM,2004;350:2129 *Lynch T et al.*

Conclusions:

- Screening for specific EGFR mutations may identify sensitive patients to gefitinib.
- Structural analysis of the mutant receptors may help understand the mechanism of EGFR activation and help the design of more specific inhibitors of the mutant receptors.

DNA repair genes:

PROGNOSTIC FACTORS IN LUNG CANCER: ERCC1 & RRM1

ASCO '03. Abs # 2590. ***R Rosell et al.***

ERCC1 ***(DNA repair)*** & **RRM1** expression predicts response to platinum and OS in advanced disease.

81 pts, Stage-IIIB "wet" or –IV, Rx'd with Cis/Gem

	TTP	**MS**	**Ideal Rx**
Low ERCC1	**8.3mo**	**13.7mo**	**Cis/Gem**
High ERCC1	5.1	3.6	**Other Rx**
Low RRM1	**8.3**	**N/R**	**Cis/Gem**
High RRM1	2.7	6.8	**Other Rx**

ERCC1 mRNA-based, Ph-III-r trial in Stage-IV NSCLC:

192 pts. available for analysis

Design:



ASCO 2005, Abstract #7002; Rosell R et al.,

ERCC1 mRNA-based, Ph-III-r trial in Stage-IV NSCLC:

ERCC1	?	Low	High
	A Cis/Doc	B1 Cis/Doc	B2 Gem/Doc
ORR	40.4%	56.6%	37.7%
A1-Low Cis/Doc 47.3%	A2-High Cis/Doc 26.1%	p=0.08	

ASCO 2005, Abstract #7002; Rosell R et al.

ERCC1 mRNA-based, Ph-III-r trial in Stage-IV NSCLC:

Conclusions:

1. **Low ERCC1 expressers:** better than average response to Platinum-based therapy (doc/cis) ***[56.6%].***
2. **High ERCC1 expressers:** trend to better response to a non-Platinum regimen (doc/gem).
   [ORR 37.7 vs. 26.1 %; MS 9.5 vs. 8.0 mo.]

ASCO 2005, Abstract #7002; Rosell R et al.,

ERCC1 mRNA-Based Customized Chemotherapy Trial: Survival Analysis

Cisplatin/Taxotere therapy



TREATMENT

SMOKING CESSATION:

Chantix^{R} (*varenicline tartrate*) daily for 12 weeks + 12 extra weeks for pts who quit smoking to increase likelihood of long-term smoking cessation.

COMMENT: Chantix^{R} ***(Pfizer)*** was approved by the FDA in 6/06 to help smokers stop smoking *(eases withdrawal symptoms and blocks nicotine effects if pts resume smoking)* based on six clinical trials (3,659 pts, average 21 cigarettes/day x 25 years). Chantix was superior to placebo in all trials, and superior to Zyban *(bupropion)* in 2:5 placebo-controlled studies. Major adverse effects: N/V, HA, flatulence, insomnia, abnormal dreams, and dysgeusia (change in taste perception)

SCREENING: Low dose spiral CT-scan in early diagnosis of LuCa:

Conclusions:

1. Effective in early diagnosis
2. Potential increase in cure rate
3. Very low rate of procedures for benign dz.

National Lung Screening Trial (NLST)

American College of Radiology Imaging Network [ACRIN]

Spiral CT-scan ***vs.*** CxR

http://www.cancer.gov/nlst

CHEMOPREVENTION:
SWOG E5597
(NCCN 2006)

Design: double blind, placebo controlled study of **selenium yeast**, 1tablet/day x**4 years *vs***. placebo, 1 tablet in AM x 4 years.

Eligibility:

1. Totally resected **Staged IA *(pT1N0)***
2. Free of disease.
3. 6 - 36 months from date of surgical resection
4. No prior or current chemo or radiation therapy
5. ECOG PS 0-1

Journal of the National Comprehensive Cancer Network; July 2006

NSCLC: Therapeutic Options by Stage[4]

Stage	Treatment Options	5-Year Survival
IA	Surgery	>70%
IB	Surgery ± Adjuvant CT	60%
IIA	Surgery + Adjuvant CT	50%
IIB	Surgery + Adjuvant CT	30-40%
IIIA (N2-) IIIA (N2+)	Surgery + Adjuvant CT CT ± XRT ± Surgery	25-40% 10-30%

4 *Cancer Principles & Practice of Oncology.* Philadelphia: Lippincott Williams & Wilkins; 2001:925-974.

Case #1:

MW- *initial visit: 11/10/05*

62 y/o WF, with recurrent RUL pneumonias between July and October, 2005. Repeat CxR after ATBx therapy showed **R hilar mass**. Chest CT-scan showed a 4.58 x 4.23 cm RUL pulmonary mass with possible direct extension to the medial pleura, possible R paratracheal and pre-carinal LN's, a 2.5 x 1.6 cm **L adrenal lesion**, and a **L1 lytic lesion**.

Transbronchial Bx of the RUL mass showed **large cell undifferentiated** carcinoma of the lung. Bx of the L1 lesion was reported as benign.



Case #1:

A whole body PET-scan showed the adrenal mass and the possible bony lesions NOT to be hypermetabolic. Clinical *(c)***stage IIIA (T2N2M0).**

Therapeutic recommendation upon consultation to the Multidisciplinary Lung Cancer Clinic: **"neo-adjuvant combined modality concurrent chemo-radiation therapy *f/b* re-evaluation with intent to resection".** Patient was treated with two cycles of cisplatin *(60 mg/m2)* and etoposide *(120 mg/m2/day x3),* every 3 weeks with concurrent XRT *(50 Gy over 25 treatment fractions)* to the tumor and adjacent positive adenopathies and areas of likely sub-clinical involvement.

Case #1:

Interval re-evaluation was planned for after completion of chemoradiation. If the patient was not found a candidate for surgery, she was to continue XRT to a definitive dose up to 65 Gy and consolidation chemotherapy with two cycles of docetaxel 100 mg/m2 every 3 weeks.

Upon completion of chemoradiation, a chest CT-scan was done showing objective response as per table:

	10/31/05	2/14/06
RUL mass	4.58 x 4.23 cm	3.0 x 2.3 cm
L adrenal mass	2.5 x 1.6 cm	2.45 x 1.58 cm

Case #1:

On 4/4/06 the patient underwent a VATS RULobectomy with chest wall resection.

Tumor size	3.5 cm
Histologic type	Large cell undiff.
Histologic grade	G4
Extent of invasion	Visceral/parietal pleura
Margins	uninvolved
Venus invasion	No
Arterial invasion	No
N1 nodes (station 10-14)	0:1
N2 nodes (station 1-9)	0:2 ← **Total LN's sampled: 3**
N3 nodes	0:0
Distant metastais	Not examined

Case #1:

The second week in May the patient developed persistent HA's and weakness. Brain MRI with contrast showed a **single R occipital mass** c/w metastasis.

Upon consult with NS the mass was debulked and she received **30 Gy** in 12 treatment fractions to the whole brain, from 5/24 through 6/12/06, plus **temozolamide** *(75mg/m2/day).*



Case #1:

On 5/23/06 she was sent for a whole body CT/PET scan for restaging of the LuCa and due to progressive **pain in the R paraspinal area**, at T8-9 level.





A new, abnormal focal area of hypermetabolism was found along the paramedial aspect of the posterior R pleura at T9 level with SUV of 9.1. Bx proved this to be **NSCLC, metastatic.**

Case #1:

She received **35 Gy** delivered in 7 treatment fractions, using IMRT, from 6/21 through 6/29/06.

On 7/25/06 a thoracic and lumbar spinal MRI was done due to progressive back pain. It showed metastatic **disease to T10** with **tumor extension into the neural foramina** and chronic compression of L1.





Case #1:

On 7/27/06 the patient was seen last in the office with significant deterioration of her condition, confused and with 7-8:10 pain in the mid/low back, even on combined narcotic analgesia.

At this point she and her family requested **terminal care with Hospice** at home.

NSCLC: Therapeutic Options by Stage (cont)[4]

Stage	Treatment Options	5-Year Survival
IIIB (N2-3)	CT/TRT ± CT	<10%
IIIB T4N0	CT/TRT ± Surgery	<5%
IIIB (with pleural effusion)	CT, MTT	<2%
IV	CT, MTT	
	Palliative Radiation	
	Symptom Management	

4 *Cancer Principles & Practice of Oncology.* Philadelphia: Lippincott Williams & Wilkins; 2001:925-974.

EARLY STAGE

adjuvant therapy

TNM* Staging of NSCLC[3]

Stage IA	T1	N0	M0	
Stage IB	T2	N0	M0	
Stage IIA	T1	N1	M0	
Stage IIB	T2 T3	N1 N0	M0 M0	

*T = primary tumor; N = nodal involvement; M = distant metastasis

3 *Seminars in Surgical Oncology.* 2000;18:106-115.

TNM* Staging of NSCLC (cont)[3]

Stage IIIA	T1-3 T3	N2 N1	M0 M0	

*T = primary tumor; N = nodal involvement; M = distant metastasis

3 *Seminars in Surgical Oncology.* 2000;18:106-115.

TNM* Staging of NSCLC[3]

Stage IA	T1	N0	M0	

NO INDICATION for ADJUVANT THERAPY

*T = primary tumor; N = nodal involvement; M = distant metastasis

3 *Seminars in Surgical Oncology.* 2000;18:106-115.

TNM* Staging of NSCLC[3]

Stage IB	T2	N0	M0	

A. On **clinical trial**, if available

B. **High-risk** patients *(angiolymphatic invasion, high histologic grade, high nuclear grade)*

*T = primary tumor; N = nodal involvement; M = distant metastasis

3 *Seminars in Surgical Oncology.* 2000;18:106-115.

Adjuvant chemotherapy for Stg IB NSCLC:

CALGB 9633:

Design: 13% OS impr./50% 5-y S.

Median F/U: 34mo

344 pts.

Stage IB *(T2N0)*

Lobectomy 89%

RANDO

	4-yS	4-yFFS
Cb-6/Pacl-200 q 21 days x 4 cycles	**71%**	**61%**
Observation	59%	50%
pValue	***0.028***	***0.035***

GM Strauss et al., PASCO 2004

Adjuvant chemotherapy for Stg IB NSCLC:

CALGB 9633:

344 pts ***150 deaths*** **54 mo F/U**	**2004**	**2006**		
	4-yS	**5-yDFS**	**OS**	**5-yS**
Paclitaxel-200 Carbopl-6 q21d x 4 cycles	**71%**	**HR: 0.74**	**HR: 0.80**	**60%**
Observation	**59%**	**1.0**	**1.0**	**57%**
pValue	***0.028***	***0.027***	***0.10***	***0.32***

GM Strauss et al., PASCO 2006, Abstr 7036

TNM* Staging of NSCLC[3]

Stage IIA	T1	N1	M0	
Stage IIB	T2 T3	N1 N0	M0 M0	

*T = primary tumor; N = nodal involvement; M = distant metastasis

3 *Seminars in Surgical Oncology*. 2000;18:106-115.

TNM* Staging of NSCLC (cont)[3]

Stage IIIA	T1-3 T3	N2 N1	M0 M0	

*T = primary tumor; N = nodal involvement; M = distant metastasis

3 *Seminars in Surgical Oncology*. 2000;18:106-115.

ANITA:

JY Douillard et al., ASCO '05, Abstr #7013

			7-yS
840 pts. Stage **IB**/II/IIIA	RANDO	Cis-50/Vin-25 q 28 days x 4 cycles	**45%**
		Observation	37%

5-y S.	Stg-IB	Stg-II	Stg-III
Treatment	**62%**	**52%**	**42%**
Observation	**63%**	39%	26%

Adjuvant chemotherapy in early stage NSCLC :

Consensus:

1. Chemotherapy of choice: **cis-based** *(Vinorelbine, VP-16, Vinca alkaloids)*
2. Patient eligibility: **Stage II & III**
3. **Stage IB:**
   a. On **clinical trial**, if available
   b. **High-risk** patients *(angiolymphatic invasion, high histologic grade, high nuclear grade)*
4. **Age** NOT a limiting factor

Adjuvant chemo in **elderly** patients: *JBR.10 (Cis/VNR)*

213 pts.	**<65**	**≥65**	**>75**
OS HR	**0.77** *p=0.084*	**0.61** *p=0.04*	**1.95** *p=0.02*
SqCellCa	32%	**49%** ***p=0.001***	--
PS 0-1	**53%** ***p=0.01***	41%	--
Dose Int. ***1. VNR*** ***2. Cis***	 13.2 18.0	 9.9 *p=0.0004* 14.1 *p=0.001*	--
Toxicity	SAME		--

Sub-set Analysis

C Pepe et al, PASCO 2006, Abstr 7009

Genomics and prognosis of early NSCLC:

Lung Metagene Model

Method: 89 pts. initial retrospective DNA microarray *(genes that predict recurrence in early NSCLC)* on long term survivors. Blinded validation in previously treated pts on trials.

Results:
- Accuracy: 79%
- PPV: 79%
- NPV: 80%

Good prognosis:	76%
Bad prognosis:	24%

Stg-I	RISK		
	low	interm	high
1-yS	93%	70%	<10%

DH Harpole et al., PASCO 2006, Abstr 7026

Genomics and prognosis of early NSCLC:

Lung Metagene Model

CALGB 30506:

(ongoing)

Prospective evaluation of risk factors in early stage NSCLC, and adjuvant chemotherapy.

DH Harpole et al., PASCO 2006, Abstr 7026

INTERMEDIATE STAGE

TNM* Staging of NSCLC (cont)[3]

Stage IIIA	T1-3 T3	N2 N1	M0 M0	

*T = primary tumor; N = nodal involvement; M = distant metastasis

3 *Seminars in Surgical Oncology*. 2000;18:106-115.

NEO-ADJUVANT CHEMOTHERAPY

resectable disease

Surgery alone *vs.* pre-Op. Carbo/paclit. in Stage-IB & **non-N2** -IIIA NSCLC:

S9900

RESECTABLE

Population:
- **Stage-IB (63%)**
- **Stage-IIA/B (33%)**
- Stage-IIIA (4%)

96%

Primary endpoint: 30% improvement in MS ***(3.6 yrs)*** over surgery alone ***(2.7 yrs).***

Surgery: at least lobectomy with mediastinal LN sampling.

ASCO 2005 LBA # 7012. C Pisters et al.

Surgery alone *vs.* pre-Op. Carbo/paclit. in Stage-IB & **non-N2** -IIIA NSCLC:

S9900

~~>700~~

354 pts., randomized 1:1.

RANDOMI → **Pacl-225 / Carb AUC6 / q 3w x 3** → SURGERY

Treatments	OS	1-yS	2-yS	HR
Pacl-225 / Carb AUC6 / q 3w x 3 → SURGERY	42m	82%	68%	0.88
SURGERY	37m	79%	64%	1.0

ASCO 2005 LBA # 7012. C Pisters et al.

Resectable **non-N2 NSCLC:**

Consensus:

1. **Resectable** non-N2 disease, should be offered **definite R0 intervention**, with at least **4 regional LN's** sampling.
2. **Borderline resectable** non-N2 disease, can be treated with **induction therapy** *(Carbo or Cis-based doublet for 2-3 cycles)* ***f/b.*** re-evaluation for resection.

NEO-ADJUVANT
CHEMO/RADIATION THERAPY

resectable disease
ROLE OF SURGERY?!

Phase-III CHRT vs. CHRT f/b Surgery in Stage-IIIA **(pN2)** NSCLC: *RTOG 9309*

RESECTABLE

Primary endpoint: PFS, OS

	396 pts.	**PFS**	**5-yPFS**	**OS**
RANDO	PEx2+TRT-45Gy >> **Surg** >> PEx2	**12.8** m	**22.4** %	23.6 m
	PEx4+TRT-61Gy	10.5	11.1	22.2
	pValue	***0.017***	***0.008***	***0.24***

ASCO 2005, Abstract #7014; Albain K et al.

Phase-III CHRT vs. CHRT f/b Surgery in Stage-IIIA (pN2) NSCLC:
RTOG 9309

Conclusions:

1. Significant improvement in **PFS** but **not OS** when surgery follows CHRT in Stage-IIIA **(pN2)**
2. Trend for better 5-y Survival with **trimodality** therapy.

ROLE OF SURGERY??

ASCO 2005, Abstract #7014; Albain K et al.

MANAGEMENT OF LOCALLY ADVANCED LUNG CANCER:

unresectable disease

TNM* Staging of NSCLC (cont)[3]

Stage IIIB	T4 Any T	Any N N3	M0 M0	

*T = primary tumor; N = nodal involvement; M = distant metastasis

3 *Seminars in Surgical Oncology*. 2000;18:106-115.

SWOG 9504
Stage-IIIB

UNRESECTABLE

***83 Pts.* Stage-IIIB T4 & N3**

INDUCTION	CONSOLIDATION
Cis *50mg/m2* d1,8,29,36 VP-16 *50mg/m2* d1-5; 29-33 XRT *61 Gy*, from d1	▶ TXT *75-100mg/m2* q 21days x 3 cycles

Results:	MS-Mo	1-Y	2-Y	3-Y
	27	76%	54%	40%

D Gandara et al, ASCO 2001; Abs.#1255

SWOG 9504

	2005	
5-y MS	26mo	T4N0-1: 32 T4N2: 26 N3: 16
1-Y S	76%	
2-Y S	54%	
3-Y S	40%	
5-Y S	29%	T4N0-1: 29 T4N2: 37 N3: 20

Gandara D et al. ASCO '05, Abs #7059

ADVANCED DISEASE

TNM* Staging of NSCLC (cont)[3]

Stage IV	Any T	Any N	M1	

*T = primary tumor; N = nodal involvement; M = distant metastasis

3 *Seminars in Surgical Oncology.* 2000;18:106-115.

Goals in Advanced NSCLC [4]

- **Extend Survival**
  1st-, **2nd-, and 3rd-line options**
- **Improve Quality of Life**
  Palliate disease-related symptoms
  Manage treatment-related side effects
  Support patient and family turmoil

Provide the Longest Duration of Quality of Life!!!

4 *Cancer Principles & Practice of Oncology.* Philadelphia: Lippincott Williams & Wilkins; 2001:925-974.

Agents with "Activity" in Advanced NSCLC[5,6]

Older	Newer	Newest
Cisplatin	Carboplatin	Pemetrexed**
Etoposide	Docetaxel	Erlotinib
Ifosfamide	Irinotecan	Gefitinib
Mitomycin-C	Gemcitabine*	Bevacizumab
Vinblastine	Paclitaxel	
Vindesine	Topotecan	
	Vinorelbine	

Note: Not all these agents are approved by the FDA for the treatment of NSCLC.
*Gemcitabine/cisplatin is approved for 1st-line NSCLC
**Pemetrexed is approved for 2nd-line treatment of NSCLC

5 *ACCC Drug Bulletin.* 2005;14(4):14.
6 Seminars in Oncology. 2005.

Think research…!!!

PFIZER A8501001

1st line induction chemotherapy +/- dendritic cell vaccine in advanced NSCLC.

Eligibility: Stage IIIB *(with pleural effusion)* and Stage IV NSCLC.

Design:

Arm-A: Carboplatin AUC-6/Paclitaxel 200 mg/m2 on d1, every 21 days, x 6cycles, plus **DNA recombinant dendritic cell vaccine.**

Arm-B: Carboplatin AUC-6/Paclitaxel 200 mg/m2 on d1, every 21 days, x 6cycles.

Advanced NSCLC:

Significant improvement in MS of @ 8 weeks, with **NO negative financial impact** or **on QOL**.

*Stephens RJ: **The Big Lung Trial**: Cisplatin-based chemo vs. BSC only in NSCLC. PASCO 21: 291, 2002. Abs. #1161*

Comparative table:

	RR %	TTP mo	**MS mo**	1-yS %	2-yS %	Author
Carbo/Paclit						Belani
Carb/Pacl/Bevacizumab	27	6.4	**12.5**	--	--	Sandler
Carbo/Gem	34	5.2	7.6	31.0	8.0	Tritt
Cis/Taxotere	32	--	11.3	--	**21**	Fossella
Gem/Paclit	44	4.79	8.4	33.0	8.0	Tritt

ADVANCED DISEASE

age factor

Cisplatin-based chemo in the elderly:
MILES-2P

169 pts *≥ 70 y/o* *ECOG 0-1*	**Toxicity**	**ORR**	**DFS**	**OS**
Cisplat-60 d1 **Gem-1000 d1,8** **q21d x 6 cycles**	anemia 5% thromb 10% cardiac 10% renal 7%	**43 %**	**25 wks.**	**44 wks.**
Cisplat-40 d1 **Vinor-25 d1,8** **q21d x 6 cycles**	**death 2pts.** *(sepsis; cardiac)*	36 %	21 wks.	33 wks.

Conclusions: **Cis-60/Gem is safe and active in fit elderly patients.**

F Perrone et al., PASCO 2006, Abstr 7037

TARGETED THERAPY



EGFR:



EGFR-Targeted Approaches



Adapted from Noonberg and Benz. *Drugs*. 2000;59:753.

Prospective erlotinib trial in advanced NSCLC with EGFR-mut.: *SLCG*

Back.: EGFR-mut predicts response (60-90%) and long TTP (12-21 mo) to the tk-inhibitors erlotinib & gefitinib.

Population: 127 (15.1%):1047 pts. ERGF-mut (+) ***(exon 19 & 21)***

M-age	68	Stg-IV	90%
Female/male	65%	AdenoCa	75%

Eligibility & treatment:

Stg IIIB/IV
EGFR-mut (+)*
PS 0-2
→ **Rx naïve: 67**
→ **Prior Rx: 60**
→ **Erlotinib 150 mg/day PO**

L Paz-Ares et al., PASCO 2006 Abstr7020

Prospective erlotinib trial in advanced NSCLC with EGFR-mut.: *SLCG*

Results:

	MS (mo)	1-y S (%)	CR (%)	RR (%)
Exon-19-mut	33	82	**20**	**95**
Exon-21-mut			5.5	68

Response by site: . . . . .

POOR:	GOOD:
Lung	CNS
Lymph nodes	Liver
	Bone

Prospective erlotinib trial in advanced NSCLC with EGFR-mut.: *SLCG*

Conclusions:

Prospective predictors of response to tk-inhibitors:

a. EGFR-mut (exon-19 > 21)…p=0.038

b. Non-smoking history…… p=0.043

c. Female gender…….. p=0.203

L Paz-Ares et al., PASCO 2006 Abstr7020;

CHEMO-TARGETED THERAPY IN ADVANCED NSCLC

Targeting VEGF

Bevacizumab

rHu-MoAb to VEGF-A



Bevacizumab plus chemotherapy has provided a survival advantage to patients with metastatic **colorectal carcinoma**.

VEGF as a target for the tratment of Cancer:

- **Tumors require new blood vessel growth**
- A number of pro-***(PAF)*** and anti-angiogenic factors ***(AAF)*** discovered over the past years.
- **VEGF is critical angiogenic factor for new blood vessel growth**
- VEGF overexpression is associated with disease progression and death

VEGF as a target for the tratment of Cancer:

- **Bevacizumab *(Avastin^R; Anti-VEGF Ab)* precludes VEGF from binding to VEGFR**
- Activity as single agent and in combination with cytotoxic agents
- Initial clinical trials disappointing.
- Recent successful trials:

  ASCO '03: CRC.

  ECOG 4599 '05: NSCLC

VEGF as a target for the tratment of Cancer:



VEGF as a target for the tratment of Cancer:



VEGF as a target for the tratment of Cancer:



VEGF as a target for the tratment of Cancer:



Jain et al, Nature Medicine, 2004

Carbo/Paclit +/- **Bevacizumab** *(Adenocarcinomas)*

Objective: 30% improved MS ***(8.0>10.4 mo.)***

Eligibility:
Stage-IIIB/IV
Non-surgical
ECOG ≤1

RANDOMIZE 1:1

- Carbo-6/Taxol-200, q 21 days, x 6 cycles
- Carbo-6/Taxol-200 + Bevaciz 15 mg/kg, q 21 d, x 6 cycles *f/b* Bevacizumab until DP

Sandler A et al., IASLC 2005, Abstr #86; ASCO 2005. LBA#4.

Carbo/Paclit +/- **Bevacizumab**

842 (650= 72.2% dead)	**RR %**	**PFS mo**	**MS mo**
Carbo/ Taxol	10	4.5	10.2
Carbo/ Taxol/ **Bevaciz.**	**27**	**6.4**	**12.5**
pValue	*0.0001*	*0.0001*	*0.0075*

Sandler A et al., IASLC 2005, Abstr #86; ASCO 2005. LBA#4.

Survival by Treatment



Carbo/paclitaxel +/- bevacizumab: unplanned subset survival analysis by gender

ECOG 4599

850 pts.	**PC**	**PCB**	**pValue**
MS	10.3 mo	**12.3 mo**	*0.003*
Males	**8.7 mo**	**11.7 mo**	***0.001***
Females	**13.1 mo**	**13.3mo**	***0.87***

	Males	**Females**
PFS	6.3 mo	6.2 mo
ORR	23.6 %	**38.5%**
TTP	6.8 mo	6.8 mo

JR Brahmer et al., PASCO 2006, Abstr 7036;

Carbo/paclitaxel +/- bevacizumab: unplanned subset survival analysis by gender
ECOG 4599

Toxicity - PBC Arm			
	HTN %	**Constip %**	**Abd Pain %**
Male	4.2	1.4	0.9
Female	**9.9**	**4.7**	**5.2**
pValue	***0.02***	***0.05***	***0.01***

JR Brahmer et al., PASCO 2006, Abstr 7036;

Carbo/paclitaxel/bevacizumab
female patients

Consensus:

1. Female patients **should be offered** bevacizumab-based Carbo/Paclitaxel combinations, until further gender data is available

Retinoids:
mechanism of action



Retinoids:
mechanism of action



RXR partners (P):
NGFI-B (α,β,γ)
CAR (α,β)
RAR (α,β,γ)
PPAR (α,δ,γ)
FXR
SXR
LXR (α,β)

Cell cycle control:
(regulation of cyclins and Cdk inhibitors)
Apoptosis:
(regulation of cell death genes)
Differentiation:
(adipogenesis, epithelial cell maturation)
Metabolism:
(glucose homeostasis, cholesterol efflux)

Langenfeld J et al, PNAS (USA) 94:12070,1997.

Retinoids:
RxR-β tumor expression and survival in resected NSCLC

	Pts #	**5-y S**
High ***(>12.9)***	**27**	**74.1%**
Low ***(<12.9)***	**61**	**34.4%**
		p =.0005

Brebender et al. Clin Cancer Res. 8:438-443; 2002.

Bexarotene:
clinical experience

Concurrent bexarotene and chemotherapy in advanced NSCLC:

Design: Plat- Based CH + bexarotene.

Phase-I/II (43 pts.)	OR %	MS mo	1-y S %	2-y S %	3-y S %
L1069-18					
Cis/Vin+Bexarotene ***(100/30-15 400mg/m2/d)***	**25**	**14**	**61**	**32**	**19**
All dose groups	**--**	***11.7***	**--**	**--**	**--**
TAX326 (Cis/Vin)	**--**	**10.1**	**--**	**--**	**--**

FR Khuri et al. J Clin Oncol; 19:2626,2001

ECOG 1594: *survival curve*



L1069-18 superimposed on E1594: *survival curve*



Concurrent & *sequential* bexarotene and chemo. in advanced NSCLC:

*Design: Plat- Based CH + vs. **f/b.** bexarotene.*

Phase-II (56 pts.)	OR (%)	TTP (days)		1-y S (%)		MS (mo)	
Carb-6/Tax-100/ bexarotene-400	**58** ***(PR)***	**166.2**		**45**		11.7	
		C	**S**	**C**	**S**	**C**	**S**
		162	**171**	**50**	**43**	**12.6**	**10.8**

11 pts are still alive **407** to **1036 days** from registration on the trial.

Bordoni RE et al. Pro ASCO 2006.

LOOKING INTO THE CRISTAL BALL:

EMERGING OF A NEW PARADIGM IN THE TREATMENT OF LUNG CANCER.

OLD THERAPEUTIC PARADIGM:	NEW THERAPEUTIC PARADIGM:
❖ Tumor Anti-proliferative drugs	❖ Modulators of tumor cell growth *("cytostasis")*
❖ Maximal cytoreduction ➢ CR/PR/SD/PD (CT-scan)*	❖ Maximal functionality ➢ TTP/MS/OS/QOL (PET)*
❖ Eradication of malignant cell clone/Cure	❖ Delay disease progression/tumor proliferation
❖ Severe nonspecific toxicity	❖ Less nonspecific toxicity

CANCER AS A CHRONIC DISEASE ⇒ PROTRACTED USE OF THERAPY ⇒ CHRONIC TOXICITY



2006 TREATMENT OF CANCER:

CONCLUSIONS:

HOPE